Initiation of a collaboration with Paris-Diderot University to discover new drugs against adenoviruses

ENYO Pharma announces its collaboration with Paris-Diderot University, Inserm Unit U941 (Institut Universitaire d’Hématologie), leaded by IDF Innov SATT, to discover new drugs against adenoviruses. The collaboration, built upon ENYO Pharma’s unique approach inspired by viruses, will identify new human cellular targets and pathway essential for replication of adenoviruses. This information will help to select experimental or clinical-stage small molecules that will be tested in a drug repositioning strategy. ENYO pharma will provide its peptide and small molecule libraries to the University team which will screen and analyse their impact on adenoviruses’

Read more »

Published on 18/10/2017

Insight Success – ENYO Pharma: Leveraging viruses to develop first-in-class drug candidates in many indications

http://www.insightssuccess.com/enyo-pharma-leveraging-viruses-to-develop-first-in-class-drug-candidates-in-many-indications

Published on 16/10/2017

Galien Medstartup Award 2017

October 25-26, 2017

New York, USA

“Presented by the Galien Foundation and Business France, the Prix Galien – MedStartUp Award encourages and rewards the most promising startups in Healthcare formed through international partnerships between French, Israeli, and North American innovators. The program brings together companies from the pharmaceutical, biotechnology, medical technology and healthcare industries, where innovation, scientific excellence and commercial goals are paramount” (galienfoundation.org)

ENYO Pharma is proud to announce its participation to the 4th Galien Medstartup 2017 program in New York on October 25-26th.

Read more »

Published on 11/10/2017

Bref Rhône Alpes – Novadiscovery et ENYO Pharma ensemble contre l’hépatite B

https://www.brefeco.com/actualite/energie/novadiscovery-et-enyo-pharma-ensemble-contre-lhepatite-b

Published on 04/10/2017

ENYO Pharma pursues its international strategy and opens a new subsidiary in Australia

ENYO Pharma has opened its first wholly owned subsidiary in Australia. This office will be our new center to manage clinical trials in the Asia-Pacific region. ENYO Pharma has based its innovation on mimicking virus strategies to discover new cellular targets and develop drug candidates in infectious diseases and beyond.

Read more »

Published on 26/07/2017